Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the First Quarter Ascendis Pharma Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message by if your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would like to hand the conference over to your first speaker today, Chad Vice President of Investor Relations. Please go ahead. Thank you, operator, and thank you everyone for joining our first quarter twenty twenty six financial results conference call. I'm Chad Fujair, Vice President, Investor Relations at Ascendis Pharma. Joining me on the call today are Yan Mikkelsen, President and Chief Executive Officer Scott Smith, Chief Financial Officer Sherry Glass, Chief Business Officer and Jay Wu, EVP and President, U. S. Market. Before we begin, I'd like to remind you that this conference call will contain forward looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to, statements regarding our commercialization and continued development of DURVYPATH, UVWell, and SKYYTORAFA, as well as certain expectations regarding patient access and financial outcomes, our pipeline candidates, and our expectations with respect to their continued progress and potential commercialization, our strategic plans, partnerships and investments, our goals regarding our clinical pipeline, including the timing of clinical results and trials, our ongoing plann...